You are here: Industry Insights > Aquestive Therapeutics

News List

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film Drugs
December 27, 2021
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems...
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant (diazepam) Buccal Film drugs
July 20, 2021
Aquestive Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil firstwordpharma
May 10, 2019
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics ...
Aquestive Therapeutics Launches Sympazan americanpharmaceuticalreview
December 03, 2018
Aquestive Therapeutics has launched Sympazan (clobazam) oral film with availability nationwide through retail pharmacies and mail order.....